The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

NCT04929080 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

149

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinom
Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
BIOLOGICAL: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
BIOLOGICAL: JS001 and JS004

Sponsor

Shanghai Junshi Bioscience Co., Ltd.